irbesartan - Profile

What are the generic drug sources for irbesartan and what is the scope of freedom to operate?

Irbesartan is the generic ingredient in two branded drugs marketed by Sanofi Aventis Us, Ajanta Pharma Ltd, Alembic Pharms Ltd, Amneal Pharms, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Molecular, Chartwell Rx, Hetero Labs Ltd V, Hikma, Hisun Pharm Hangzhou, Ipca Labs Ltd, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, MSN, Prinston Inc, Sandoz, Sciegen Pharms, Teva Pharms, Unichem, Watson Labs Inc, Yiling, and Zydus Pharms Usa Inc, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are three tentative approvals for this compound.

Summary for irbesartan

US Patents:	0
Tradenames:	2
Applicants:	24
NDAs:	24

Generic filers with tentative approvals for IRBESARTAN

Applicant	Application No.	Strength	Dosage Form
		300MG; 25MG	TABLET; ORAL
		300MG; 12.5MG	TABLET; ORAL
		150MG; 12.5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for IRBESARTAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVAPRO	Tablets	irbesartan	75 mg, 150 mg and 300 mg	020757	1	2004-05-25

US Patents and Regulatory Information for irbesartan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-001	Sep 30, 1997		DISCN	Yes	No
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-002	Sep 30, 1997	AB	RX	Yes	No
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-003	Sep 30, 1997	AB	RX	Yes	Yes
Ajanta Pharma Ltd	IRBESARTAN	irbesartan	TABLET;ORAL	203685-001	Dec 10, 2015		DISCN	No	No
Ajanta Pharma Ltd	IRBESARTAN	irbesartan	TABLET;ORAL	203685-002	Dec 10, 2015		DISCN	No	No
Ajanta Pharma Ltd	IRBESARTAN	irbesartan	TABLET;ORAL	203685-003	Dec 10, 2015		DISCN	No	No

Expired US Patents for irbesartan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-001	Sep 30, 1997
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-003	Sep 30, 1997
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-003	Sep 30, 1997
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-002	Sep 30, 1997
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-001	Sep 30, 1997
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-002	Sep 30, 1997

EU/EMA Drug Approvals for irbesartan

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Sanofi Winthrop Industrie	Karvea	irbesartan	EMEA/H/C/000142Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal product regimen.	Authorised	no	no	no	1997-08-26
Sanofi Winthrop Industrie	Aprovel	irbesartan	EMEA/H/C/000141Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.	Authorised	no	no	no	1997-08-26
Zentiva k.s.	Irbesartan Zentiva (previously Irbesartan Winthrop)	irbesartan	EMEA/H/C/000785Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.	Authorised	no	no	no	2007-01-19
Teva B.V.	Irbesartan Teva	irbesartan	EMEA/H/C/001093Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.	Authorised	yes	no	no	2009-10-30
Krka, d.d., Novo mesto	Ifirmasta (previously Irbesartan Krka)	irbesartan	EMEA/H/C/000962Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.	Authorised	yes	no	no	2008-12-01
Pharmathen S.A.	Sabervel	irbesartan	EMEA/H/C/002510Sabervel is indicated in adults for the treatment of essential hypertension.It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.	Withdrawn	yes	no	no	2012-04-13

Irbesartan: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary
Irbesartan, an angiotensin II receptor blocker (ARB), primarily prescribed for hypertension and diabetic nephropathy, remains a commercially significant pharmaceutical. Despite its patent expiry in major markets, it sustains relevance via generic competition, landscape shifts in cardiovascular therapies, and evolving regulatory and market dynamics. This report provides a comprehensive analysis of irbesartan’s current investment scenario, key market drivers, competitive landscape, and forecasts its financial trajectory over the next five years.

---

1. Introduction to Irbesartan and Market Context

• Chemical Class: Angiotensin II receptor blockers (ARBs)
• Mechanism of Action: Selectively blocks the angiotensin II receptor, reducing blood pressure.
• Approval: First approved by the US FDA in 1997; marketed by Sanofi, among others.
• Indications: Hypertension, diabetic nephropathy, heart failure.

2. Market Dynamics and Key Drivers

Factor	Impact	Details
Patent Expiry and Generic Entry	Market migration	Patent expired in the US (2019) and EU (2018); increased generic competition has reduced prices but expanded access.
Prevalence of Hypertension & Diabetes	Demand stability	Over 1.2 billion adults globally diagnosed with hypertension; increase in diabetes (~10.5% globally), both primary population for irbesartan.
Regulatory Landscape	Market access	Stringent quality standards; recent approvals of biosimilars influence dynamics.
Competitive Alternatives	Market share shifts	Other ARBs (losartan, valsartan, olmesartan) compete, alongside emerging therapies (SGLT2 inhibitors, GLP-1 receptor agonists).
Cost-Effectiveness and Safety Profile	Prescribing trends	Favorable safety profile sustains usage; cost competitiveness favors generics in budget-conscious markets.
COVID-19 Pandemic Impacts	Market fluctuations	Short-term disruptions, but long-term demand continues as cardiovascular comorbidities remain high.

3. Investment Opportunities and Challenges

Opportunities	Challenges
Generics Market Growth	Price erosion post-patent expiry continues, impacting margins.
Portfolio Expansion	Mild therapeutic differentiation limits premium pricing potential.
Emerging Markets	Market penetration challenges due to regulatory barriers and purchasing power.
Biosimilar and Fixed-Dose Combination Products	Competition from new formulations and combination therapies.
R&D for New Indications	Limited pipelines and patent strategies focusing elsewhere.

---

4. Competitive Landscape

Key Players	Market Share (Estimate, 2022)	Strategic Moves	Notes
Sanofi	Approx. 20%	Transition to generics, focus on biosimilars	Lost patent exclusivity; now mainly generics.
Teva Pharma	Approx. 25%	Focus on affordability and volume	Major global generic manufacturer.
Mylan (now part of Viatris)	Approx. 15%	Expansion into emerging markets	Diversification of portfolio.
Others (Zylera, Sandoz, local manufacturers)	Remaining ~40%	Niche markets, regional players	Price competition intense.

5. Financial Trajectory and Forecasts (2023–2028)

Parameter	2023	2024–2028 (Forecast)	Notes
Global Sales (USD)	~$1.3 billion	Decline at CAGR of ~2-3%	Due to generic erosion and competition.
Price Trends	Stable with slight decline (~4% annually)	Continued compression in mature markets	Impact of high-volume, low-margin generic sales.
Market Penetration	High in North America and Europe	Growing in Asia, Latin America	Opportunities in emerging markets attracted by affordability.
Development Costs	Minimal (generic manufacturer focus)	Stable, focused on regulatory compliance	No significant R&D investments expected.
Profit Margins	15–20% (estimated for generics)	Slight decline, stabilized by volume	Margins sensitive to price competition.

6. Regulatory and Patent Landscape

Area	Current Status	Implications	Key Considerations
Patent Status	Patents expired (2018–2019)	Increased generics availability	Mandates price competitiveness
Biosimilars	Not applicable (small molecule)	Biosimilar entry unlikely	Biosimilars mainly for biologics
Regulatory Approvals	Broad global approvals for generics	Facilitates international sales	Import/export policies influence penetration.

---

7. Comparative Analysis of Key ARBs

Drug Name	Patent Status	Price Range (USD per unit)	Market Share	Efficacy & Safety Profile	Main Competitors
Irbesartan	Patented until ~2018; now generic	$0.10 - $0.20	High in early 2010s, declining	Well-established	Losartan, Valsartan, Olmesartan
Losartan	Patents expired (2010)	Similar	Larger market share	Well-established	Same as above
Valsartan	Patent expired (2012)	Slightly higher	Larger in certain regions	Similar	As above
Olmesartan	Patent expired (2018)	Slight premium	Growing share	Similar	As above

---

8. Future Trends and Strategic Outlook

• Post-Patent Market Stabilization: Price erosion stabilizes as generic competition saturates, especially in mature markets.
• Emerging Market Growth: Less saturated markets (Asia, Latin America) offer growth avenues; tailored regulatory strategies essential.
• Shift Toward Fixed-Dose Combinations (FDCs): Increased adoption of combination pills improves adherence, retains some premium margins.
• Therapeutic Positioning: Limited innovation; focus shifts to cost leadership, market access, and volume sales.
• Regulatory Pressures & Quality Standards: Quality assurance remains crucial to maintain market share amid regulatory scrutiny.

---

9. Key Takeaways

• Patent expiry significantly impacted irbesartan’s pricing but expanded global access.
• Generic competition has driven prices down, constraining profit margins but increasing volume-based revenue.
• Market growth is primarily driven by the global rise in hypertension and diabetic nephropathy, especially in emerging economies.
• Despite intense competition, irbesartan’s established efficacy and safety profile sustain its relevance.
• Investments should focus on geographic expansion, portfolio diversification (e.g., FDCs), and cost efficiency strategies.

---

10. Frequently Asked Questions (FAQs)

Q1: How has patent expiry affected irbesartan’s market share globally?
Patent expiry has led to a significant decline in branded sales and an increase in generic market penetration, resulting in a fragmented market with decreased profit margins but expanded volume sales.

Q2: What are the key competitors to irbesartan in the antihypertensive ARB market?
Losartan, valsartan, olmesartan, and telmisartan are primary competitors, each with its own market share and regional strengths.

Q3: Which markets present the most growth opportunities for irbesartan generics?
Emerging markets in Asia, Latin America, and Africa offer growth, driven by increasing hypertension prevalence and affordability-driven generic adoption.

Q4: Are biosimilars relevant to irbesartan’s market?
No; biosimilars apply to biologic drugs. Irbesartan, being a small molecule, faces no biosimilar competition.

Q5: What regulatory trends could impact irbesartan’s future sales?
Stringent quality standards, import/export policies, and price regulations in key markets can influence supply chain and market access.

---

References

1. WHO Global Status Report on Noncommunicable Diseases, 2014.
2. FDA Drug Approvals and Patent Data, 2019–2022.
3. IMS Health (IQVIA) Market Analytics, 2022.
4. Sanofi Annual Reports (2017–2022).
5. European Medicines Agency (EMA) Regulatory filings.

---

Conclusion
Irbesartan’s investment outlook reflects typical post-patent generic market trends: declining per-unit prices amid an expanding global hypertension treatment market. Strategic growth hinges on geographic diversification, portfolio innovation (e.g., FDCs), and value-based healthcare trends. While margins shrink, volume-driven revenues sustain overall compensation, especially in emerging markets. Continuous monitoring of regulatory shifts and competitive dynamics remains paramount for stakeholders.

---